Recent Quotes (30 days)

You have no recent quotes
chg | %

Ceapro Inc.  

(Public, CVE:CZO)   Watch this stock  
Find more results for CZO
0.000 (0.00%)
Jul 28 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.28 - 0.29
52 week 0.18 - 0.75
Open 0.28
Vol / Avg. 14,200.00/18,643.00
Mkt cap 18.20M
P/E 14.92
Div/yield     -
EPS 0.02
Shares 61.69M
Beta 1.55
Inst. own     -
Jun 1, 2015
Q1 2015 Ceapro Inc Earnings Release

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -11.31% 17.93%
Operating margin -13.16% 22.49%
EBITD margin - 27.20%
Return on average assets -9.71% 24.94%
Return on average equity -35.29% 136.43%
Employees 12 -
CDP Score - -


7824 51 Ave NW
+1-780-4214555 (Phone)
+1-780-4211320 (Fax)

Website links


Ceapro Inc. (Ceapro) is a Canada-based growth stage biotechnology company. The Company’s primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using proprietary technology, natural, renewable resources and developing innovation. The Company’s products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, which are marketed to the personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales. The Company’s Veterinary therapeutic products include an oat shampoo, an ear cleanser, and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia, through agreements with Daisen Sangyo Co. Ltd.

Officers and directors

Gilles R. Gagnon Chief Executive Officer, Director
Age: 61
Stacy Prefontaine Chief Financial Officer, Corporate Secretary
Glenn R. Rourke Independent Chairman of the Board
Ulrich Kosciessa Director
William W. Li M.D. Director
Age: 50
Donald J. Oborowsky Independent Director
John Zupancic Independent Director